Previous 10 | Next 10 |
2023-05-12 15:00:44 ET Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar ...
2023-05-11 09:49:29 ET AVROBIO press release ( NASDAQ: AVRO ): Q1 GAAP EPS of -$0.57 misses by $0.01 . As of March 31, 2023, AVROBIO had $72.3 million in cash and cash equivalents, as compared to $92.6 million in cash and cash equivalents as of Dec. 31, 2022. For...
On track to initiate registrational global Phase 2/3 clinical trial for Gaucher disease type 3 (GD3) in second half 2023, subject to regulatory alignment Plan to provide clinical and regulatory updates on cystinosis program in conjunction with ASGCT annual meeting in May 2023; plan to ini...
2023-05-01 07:43:30 ET Gene therapy company AVROBIO ( NASDAQ: AVRO ) said on Monday that CFO Erik Ostrowski has been appointed to the additional post of interim CEO, effective today. Ostrowski succeeds founding president and CEO Geoff MacKay. MacKay is leaving the com...
Current CFO Erik Ostrowski named interim CEO, replacing Founding President and CEO Geoff MacKay AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company working to free people from a lifetime of genetic disease, today announced the appointment of Erik Ostrowski as int...
2023-03-23 07:56:54 ET AVROBIO press release ( NASDAQ: AVRO ): Q4 GAAP EPS of -$0.57 misses by $0.12 . As of Dec. 31, 2022, AVROBIO had $92.6 million in cash and cash equivalents, as compared to $189.6 million in cash and cash equivalents as of Dec. 31, 2021. Based on ...
Following positive regulatory feedback, plan to initiate registrational global Phase 2/3 clinical trial for Gaucher disease type 3 (GD3) in second half 2023, subject to regulatory alignment Patient dosing completed in collaborator-sponsored Phase 1/2 clinical trial for cystinosis; plan to...
AVROBIO, Inc . (Nasdaq: AVRO), a leading clinical-stage gene therapy company working to free people from a lifetime of genetic disease, today announced that members of its senior management team are scheduled to participate in a panel titled “Orphan Neuro Corporate Panel” at Cowen...
Sangamo Therapeutics ( NASDAQ: SGMO ) added ~11% on Monday after Wedbush Securities upgraded the genomic medicine company to Outperform from Neutral, noting a recent data readout for the company's Fabry disease candidate ST-920. Announcing updated data from its Phase 1/2 STAAR cli...
Four platform presentations and two posters with data on AVROBIO’s lysosomal disorder programs to be presented AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company working to free people from a lifetime of genetic disease, today announced that updat...
News, Short Squeeze, Breakout and More Instantly...
AlloVir Inc. (ALVR) is expected to report $-0.16 for Q1 2024 Inter & Co. Inc. (INTR) is expected to report $0.08 for Q1 2024 Array Technologies Inc. (ARRY) is expected to report $-0.06 for Q1 2024 Sphere 3D Corp. (ANY) is expected to report $-0.23 for Q1 2024 Alpine Immune Sci...
Swire Pacific Ltd. ADR (Class A) (SWRAY) is expected to report for Q4 2023 Troika Media Group Inc. (TRKAQ) is expected to report for quarter end 2023-12-31 American Environmental Partners Inc. (AEPT) is expected to report for quarter end 2023-12-31 Veolia Environnement S.A. ADR (VEOEY...
NEW YORK, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potentia...